Usefulness of Carcinoembryonic Antigen for Monitoring Tumor Progression during Palliative Chemotherapy in Metastatic Colorectal Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the efficacy of carcinoembryonic antigen (CEA) measurement for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer. Materials and Methods: Forty-eight patients with initially unresectable metastatic colorectal cancer (n=26, 54.2%) or recurrent unresectable metastatic colorectal cancer (n=22, 45.8%) received FOLFOX-4 chemotherapy for palliation. Serum CEA levels and carbohydrate antigen 19-9 levels were measured and computed tomography (CT) studies were performed prior to chemotherapy and after 3 cycles of chemotherapy. From the CT images, tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors criteria and categorized as complete response, partial response, stable disease, and progressive disease. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of tumor marker assessments for determining tumor response were calculated. Results: The sensitivity, specificity and diagnostic accuracy of CEA assessment for prediction of disease progression were 50%, 77% and 69%, respectively. When the patients were dichotomized according to baseline CEA level, the initially elevated CEA group showed higher sensitivity and higher diagnostic accuracy compared to the initially normal CEA group (sensitivity=67% vs. 20%; diagnostic accuracy=71% vs. 62%). Conclusion: CEA assessment could be useful for monitoring tumor progression during palliative chemotherapy in only patients with initially elevated CEA level.
Abstract
Purpose: To evaluate the efficacy of carcinoembryonic antigen (CEA) measurement for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer. Materials and Methods: Forty-eight patients with initially unresectable metastatic colorectal cancer (n=26, 54.2%) or recurrent unresectable metastatic colorectal cancer (n=22, 45.8%) received FOLFOX-4 chemotherapy for palliation. Serum CEA levels and carbohydrate antigen 19-9 levels were measured and computed tomography (CT) studies were performed prior to chemotherapy and after 3 cycles of chemotherapy. From the CT images, tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors criteria and categorized as complete response, partial response, stable disease, and progressive disease. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of tumor marker assessments for determining tumor response were calculated. Results: The sensitivity, specificity and diagnostic accuracy of CEA assessment for prediction of disease progression were 50%, 77% and 69%, respectively. When the patients were dichotomized according to baseline CEA level, the initially elevated CEA group showed higher sensitivity and higher diagnostic accuracy compared to the initially normal CEA group (sensitivity=67% vs. 20%; diagnostic accuracy=71% vs. 62%). Conclusion: CEA assessment could be useful for monitoring tumor progression during palliative chemotherapy in only patients with initially elevated CEA level.
참고문헌 (17)
- Meyerhardt JA, "Systemic therapy for colorectal cancer", N Engl J Med, 352, pp.476~487 (2005)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~2947 (2000)
- André T, "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer", N Engl J Med, 350, pp.2343~2351 (2004)
- Kalofonos HP, "Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study", Ann Oncol, 16, pp.869~877 (2005)
- Maughan TS, "Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial", Lancet, 361, pp.457~464 (2003)
- Douillard JY, "Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial", Lancet, 355, pp.1041~1047 (2000)
- Miller AB, "Reporting results of cancer treatment", Cancer, 47, pp.207~214 (1981)
- Wang WS, "Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer", Int J Colorectal Dis, 16, pp.96~101 (2001)
- Ward U, "The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer", Br J Cancer, 67, pp.1132~1135 (1993)
- Trillet-Lenoir V, "Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?", Clin Oncol, 16, pp.196~203 (2004)
- Hanke B, "CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA)", Ann Oncol, 12, pp.221~226 (2001)
- Herrera MA, "CEA monitoring of palliative treatment for colorectal carcinoma", Ann Surg, 185, pp.23~30 (1977)
- Allen-Mersh TG, "Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer", Gut, 28, pp.1625~1629 (1987)
- Locker GY, "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer", J Clin Oncol, 24, pp.5313~5327 (2006)
- Goldstein MJ, "Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer", Cancer Invest, 23, pp.338~351 (2005)
- Duffy MJ, "Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?", Clin Chem, 47, pp.624~630 (2001)